Form 4: Janux Therapeutics Director Receives Equity Grant

Director Jake Simson was granted 5,500 restricted stock units and 15,500 stock options as part of standard compensation.

Summary

• Director Jake Simson acquired 5,500 restricted stock units (RSUs) on June 11, 2026.
• Director Jake Simson was granted 15,500 stock options with an exercise price of $13.66.
• The reporting person holds these securities for the benefit of RA Capital Management, L.P. and disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• None identified.

Risks

• Vesting of equity is subject to the reporting person's continuous service to the company.

Future Outlook

The equity grants are subject to standard vesting schedules over the next 12 months or until the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between independent directors and corporate performance.

Comparison to Industry Standards

• The grant of RSUs and options is consistent with standard director compensation packages for mid-cap biotechnology firms.
• The disclaimer of beneficial ownership is common for directors representing institutional investment firms like RA Capital.

Related Party Transactions

• The reporting person holds the securities for the benefit of RA Capital Management, L.P. and its associated funds, which offsets advisory fees.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of RSUs on June 11, 2027 or the next annual meeting.
• Vesting of stock options in equal monthly installments over 12 months.

Key Dates

Keywords

Janux Therapeutics, JANX, Form 4, Director Compensation, Equity Grant, Biotech